Skip to content

Savara SVRA Current Debt

Current Debt at other companies

ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$19.3M+72.4%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$11.81M
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$6.2M-80.5%
Insmed logo
InsmedINSM
$3.45M+12.8%
AdaptHealth logo
AdaptHealthAHCO
$24.38M+50.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$1.24M-31.2%

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's current debt?
Savara (SVRA) reported current debt of $0 in Q1 2026.
What is the long-term trend for Savara's current debt?
Over 2 years (2021 to 2025), Savara's current debt has grown at a -100.0% compound annual growth rate (CAGR), from $8.33M to $0.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.